VAT on Medication: Compassionate Access Schemes
06 Sep 2026 · Commons Chamber · 9 speeches · Official record
Commons debate API. Not a paper. A named member links to their Institrace record when we hold that seat.
It is a pleasure to respond to this debate. I thank my hon. Friend the Member for Uxbridge and South Ruislip (Danny Beales) for securing it, and for all his engagement and campaigning on this important issue. I know from my conversations with my hon. Friend that he cares deeply, as do I, about ensuring that patients can access innovative medicines, particularly when there is unmet clinical need. Free-of-charge arrangements play an important role in giving patients early access to medicines, as m... Full speech
As the changes we are discussing concern a potential tax change, I am afraid I cannot give my hon. Friend further detail about any timeline, but I reiterate that I have imparted to my officials in the Treasury and HMRC the urgency that I feel about this, and that my hon. Friend and others will share. I am glad he joins me in calling on Bayer to take confidence from what we have announced and to rejoin the early access scheme as soon as possible. I again thank my hon. Friend for securing this deb... Full speech
Speaker
Motion made, and Question proposed, That this House do now adjourn. -(Rachel Hopkins.) Full speech
I agree that we do need to find a permanent and comprehensive solution. Hopefully we can air those issues fully today. Fundamentally, the principle underlying this issue is very straightforward: if a pharmaceutical company is willing to provide a lifesaving medicine to a patient free of charge because that patient has a serious or life-threatening condition and has exhausted the available standard treatment options, the tax system should not make access to those lifesaving drugs more difficult. ... Full speech
My constituent Joseph was diagnosed with a brain tumour at just 28 years old. He was fortunate to receive early access to vorasidenib through compassionate access schemes. However, vorasidenib is only the second new NHS-approved brain cancer drug in 20 years. Does my hon. Friend agree that, given the painfully slow progress we have seen in developing treatment for brain tumours, we should be removing every possible avoidable barrier to patients receiving these promising new medicines? Full speech
I thank my hon. Friend for that. As chair of the all-party parliamentary group on access to medicines and medical devices, I have heard those stories far too often. I completely agree that we should be removing every single barrier. Full speech
The Minister is being very generous in giving way, as ever, and I appreciate his response about the limitations of the business brief process. If amending the VAT Act 1994 is the right route, does the Minister know roughly how long that would take to find a resolution? I fully his support his point about Bayer re-engaging. The Government have moved in good faith, and I hope Bayer will, too. Full speech
I begin by welcoming the Government’s decision at the start of the summer to pause the application of VAT on medicines donated for free to patients through compassionate access, early access and related schemes. The health charities, patients and industry bodies that I have worked with are grateful to Ministers for recognising that this issue needs to be addressed, and in particular for the ministerial statement setting out the Government’s intention to introduce a new approach to VAT on free-of... Full speech
I commend the hon. Gentleman on bringing forward the debate. He has hit the nail on the head on an issue that is a matter of life and death for families right across the United Kingdom. For His Majesty’s Revenue and Customs to sweep in and penalise that relief is a disgrace. Does he not agree that, although a temporary pause from the Treasury is welcome, it is simply not a solution when the clock is ticking for cancer patients and those with rare diseases, and that the Government should commit t... Full speech